Skadden advised Eyebiotech Limited, while Gibson, Dunn & Crutcher advised Merck the deal. Merck, known as MSD outside of the United States and Canada, and Eyebiotech...
Merck’s Acquisition of Eyebiotech
Mirati Therapeutics’ Merger With Bristol Myers Squibb
Kirkland & Ellis LLP advised Bristol Myers Squibb, while Skadden, Arps, Slate, Meagher & Flom LLP advised Mirat on the deal. Bristol Myers Squibb (NYSE: BMY)...